More than 40 million people worldwide die from NCDs such as cancer, diabetes, and cardiovascular disease.

Accounting for more than 70% of deaths globally, NCDs are the world’s leading cause of death and disability. They are one of the least funded health issues and burden developing countries disproportionately.

Access Accelerated is a first of its kind collective of biopharmaceutical companies committed to supporting locally led efforts to advance access to NCD prevention, treatment, and care in some of the world’s most resource-constrained countries.

Access Accelerated is an example of how private sector engagement in action can bring together a common pool of skills and expertise, coordination, information, funding, and technologies to tackle NCDs.


the expected global economic impact of the leading 5 NCDs between 2011-2030


of premature deaths from NCDs occur in LMICs


people are forced into extreme poverty every year because of NCDs

Making access to NCD care a reality 

All sectors must collaborate to strengthen health systems to achieve the UN Sustainable Development Goals and the target of reducing premature deaths from NCDs by one third by 2030.

Access Accelerated is helping create and scale sustainable solutions to achieve quality, timely, and dignified NCD prevention, treatment, and care for people living in low- and middle-income countries (LMICs).

We do this by coordinating with government-led efforts, working closely with local stakeholders, and partnering with organizations’ expert in health systems strengthening and NCDs.

Our approach

The work of Access Accelerated and our partners is guided by locally defined priorities and input from people living with these diseases. Our approach is driven by:

  • A people-first and human-centered approach
  • Strong local ownership and engagement
  • Substantive partnerships
  • Sustainable and equitable solutions
  • Innovation and continuous learning
  • Rigorous measurement and transparency

The Kenya MOH, World Bank, and Access Accelerated partnership has made unprecedented impact on the healthcare system with regards to NCD care provision and, as a result, has given hope to so many patients who now access affordable care for diabetes, hypertension, cervical and breast cancer in western Kenya.

Dr Jemima Kamano

MOI University School of Medicine

The impact of Access Accelerated

Between 2017 and 2021, 182 million people have benefited from improved access to NCD services through Access Accelerated projects.

In 2021 alone, 136 policy changes were achieved through efforts to engage national stakeholders and people living with NCDs.

As part of our relationship with the World Bank, Access Accelerated funding helped secure USD 355 million in new investments in NCDs treatment and care for LMICs along with policy change in 14 countries.

Today, the World Bank is the biggest international investor in NCDs.

Transforming how the world addresses NCDs

Actively informing global and local priority health policies that impact lives 

Alongside governments and national stakeholders, we work with our partners to build evidence that shapes outcome-oriented NCD policies and embeds scalable, sustainable, and locally owned solutions that will impact this and future generations.

Stepping up NCD investment in LMICs

We support flexible and adaptable funding that responds to emerging NCD needs, identified through evidence and data.

Setting an industry-led example for impactful, positive social change 

We focus on sharing knowledge and building trust to facilitate cross-sector partnerships to create resilient health systems for NCDs and make progress towards the UN Sustainable Development Goals, including on Universal Health Coverage.

Key lessons in advancing access to NCD care

In this key lessons report, Access Accelerated provides evidence, across its six years of impact, that stakeholders in the biopharmaceutical and life science industry can unite for a common vision to address NCDs, serving as an example of how the private sector can become a meaningful actor in processes of change towards shared societal goals.


In 2021, with the support of Access Accelerated, our partners are demonstrating progress and impact:

  • 48 health programs supported in 44 LMICs
  • 136 policy changes in LMICs
  • More than 30,000 people benefited from improved access to NCD medicines
  • Over 140,000 people were screened for NCDs, resulting in more than 10,000 diagnoses
  • More than 90,000 people benefited from improved access to NCD services
  • Over 4,000 healthcare providers received training in NCDs
  • 117 knowledge products, guidelines, and tools produced for NCD capacity-building and improved treatment and quality of care.

Strengthening partnerships

By facilitating a coordinated approach to the challenge of NCDs, Access Accelerated is enabling multisectoral collaboration built on shared systems, information, language, goals, and trust. This unlocks the potential for greater collective impact.

Supporting the Access Observatory

Led by Boston University, the Access Observatory is an independent reporting platform for private sector-led access programs.

By sharing their program information and data with the Access Observatory, Access Accelerated member companies and partners demonstrate their commitment to continuous learning, rigorous measurement, and transparency.

Learn more about Access Accelerated

Access Accelerated is doing vital work to accelerate global progress on NCDs for those who need it most. Sign up for Access Today, the Access Accelerated monthly resource of new initiatives, partnership events, noteworthy events, and more.